Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Tax Provisions (2016 - 2025)

Ani Pharmaceuticals' Tax Provisions history spans 14 years, with the latest figure at $4.0 million for Q4 2025.

  • For Q4 2025, Tax Provisions rose 213.3% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $17.5 million, up 573.01%, while the annual FY2025 figure was $17.5 million, 573.01% up from the prior year.
  • Tax Provisions for Q4 2025 was $4.0 million at Ani Pharmaceuticals, down from $7.2 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $7.2 million in Q3 2025 and bottomed at -$7.3 million in Q3 2024.
  • The 5-year median for Tax Provisions is -$1.0 million (2023), against an average of -$701157.9.
  • The largest annual shift saw Tax Provisions plummeted 57900.0% in 2022 before it surged 914.29% in 2024.
  • A 5-year view of Tax Provisions shows it stood at -$6.7 million in 2021, then surged by 78.13% to -$1.5 million in 2022, then skyrocketed by 85.91% to -$207000.0 in 2023, then plummeted by 1585.99% to -$3.5 million in 2024, then soared by 213.3% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Tax Provisions are $4.0 million (Q4 2025), $7.2 million (Q3 2025), and $2.0 million (Q2 2025).